18F-DCFpyL
18F-DCFpyL is a pharmaceutical drug with 24 clinical trials. Currently 13 active trials ongoing. Historical success rate of 88.9%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
11
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
88.9%
8 of 9 finished
11.1%
1 ended early
13
trials recruiting
24
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Multimodal Machine Learning Characterization of Solid Tumors
Clinical Trials (24)
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Multimodal Machine Learning Characterization of Solid Tumors
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
PSMA PET Registry (18F-DCFPyL)
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 24